Olema Oncology Set to Shine at Annual Healthcare Conference
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a pioneering biopharmaceutical company based in San Francisco, is taking a significant step forward by participating in the 8th Annual Evercore Healthcare Conference. This event is scheduled for an engaging fireside chat on a Wednesday in early December, an opportunity that highlights Olema's commitment to advancing targeted therapies for breast cancer and other endocrine-driven cancers.
Conference Details and Olema's Vision
During this key event, set to occur at 12:55 p.m. ET, Olema will showcase its innovative approach and ongoing projects, especially focusing on new therapies that have the potential to transform treatment norms. The biopharmaceutical landscape is evolving, and Olema is at the forefront, bringing hope to patients and healthcare providers alike through their groundbreaking research and development.
Accessible Formats for Investors
For those unable to attend in person, live webcasts and recordings of the presentation will be accessible in the company’s Events and Presentations section on its investor relations website. This approach ensures transparency and keeps shareholders informed about the latest developments within the company, further strengthening investor confidence.
About Olema Oncology and Its Groundbreaking Pipeline
Olema Oncology is dedicated to enhancing patient outcomes by advancing a robust pipeline of targeted therapies. Their flagship candidate, palazestrant (OP-1250), which is currently undergoing two Phase 3 clinical trials, exemplifies their innovative approaches. Palazestrant serves as both a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), showcasing Olema's commitment to leveraging cutting-edge science in treating breast cancer.
Expanding Horizons with Additional Drug Candidates
In addition to palazestrant, Olema is also progressing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor currently in Phase 1 clinical studies. This diversification in their pipeline underscores Olema's strategic focus on understanding and overcoming mechanisms associated with acquired resistance in cancer treatments.
Future Directions and Patient-Centric Approaches
As Olema moves forward, their focus remains firmly planted on patient-centric care. The company’s commitment shapes its research strategies, aiming to not only address breast cancer but also explore potential impacts on related cancers that could benefit from the advancements they are making. Their collaborative efforts and deep understanding of endocrine-driven cancers position Olema as a leader in the biopharmaceutical industry.
Headquarter Locations and Collaborative Operations
With a strong presence in both San Francisco and Cambridge, Massachusetts, Olema leverages regional strengths in biopharmaceutical development and research. This dual operation allows for enhanced collaboration and innovation, essential components in the fast-evolving healthcare arena.
Media and Investor Relations Contact
For more inquiries, media representatives or interested investors can reach out to Courtney O’Konek, the Vice President of Corporate Communications at Olema Oncology. She remains accessible for discussions that can further enhance interest and understanding of Olema's missions and goals.
Frequently Asked Questions
What is Olema Oncology known for?
Olema Oncology specializes in developing targeted therapies for breast cancer and has a focus on improving patient care through innovative treatments.
When will the fireside chat take place?
The fireside chat at the Evercore Healthcare Conference is scheduled for Wednesday at 12:55 p.m. ET.
What is palazestrant?
Palazestrant is Olema's lead product candidate, an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in Phase 3 trials.
How can investors access Olema’s presentation?
Investors can view live webcasts and recordings of Olema's presentations on their investor relations website following the event.
Who can I contact for more information?
You can contact Courtney O’Konek, Vice President of Corporate Communications at Olema Oncology, for further inquiries.
